FDA Bounces Request to Approve Desvenlafaxine (Pristiq) for Menopause
Pfizer Inc. reports that it has received a "complete response letter" from the Food and Drug Administration (FDA) denying its application to approve desvenlafaxine (Pristiq) for moderate to severe vasomotor symptoms of menopause such as hot flashes.
Pfizer Inc. reports that it has received a "complete response letter" from the Food and Drug Administration (FDA) denying its application to approve desvenlafaxine (Pristiq) for moderate to severe vasomotor symptoms of menopause such as hot flashes. The drug, a selective serotonin reuptake inhibitor, is currently approved for the treatment of major depressive disorder in adults.
A complete response letter states that an application for a new drug indication cannot be approved in its current form. Neither Pfizer nor FDA has released further details. Pfizer plans to pursue the application further.
Several clinical studies have shown desvenlafaxine more effective than placebo against hot flashes. One of them, a multicenter randomized trial involving more than 700 women, was published in 2008 in the journal Obstetrics and Gynecology.
How do you use the drug in your practice? Comment and vote below.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Elinzanetant's efficacy for vasomotor symptoms confirmed in phase 3 trial
March 19th 2024Bayer's OASIS 3 trial affirmsed the safety and efficacy of elinzanetant in reducing moderate to severe vasomotor symptoms, bolstering confidence in its potential as a non-hormonal solution for menopause-related issues.
Read More
